Trevi Therapeutics (TRVI) Stock Price, Quote, News & History

Q: What sector and industry does Trevi Therapeutics (TRVI) operate in?

Trevi Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Comments

Trevi Therapeutics Inc (TRVI) Stock Price, Quote, News & History

TRVINASDAQ

Trade with Public

$11.10

-0.36-3.14%

At close: Feb 9, 4:00 PM EST

$11.10

N/A

After Hours: 4:00 PM EST

Overview

News Earnings Options Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$11.41

Close

$11.10

Volume / Avg.

1.01M / 1.80M

Day Range

$10.93 - $11.46

52 Wk Range

3.77 - 14.39

Market Cap

$1.42B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

46

Short Interest

13.95%

Days to Cover

11.06

Recent Trevi Therapeutics Inc News

Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Avi Kapoor

This Adient Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Avi Kapoor

Dow Gains Over 100 Points; US Job Openings Increase In April

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-44.01M

Investing Cash Flow (TTM)

-87.37M

Financing Cash Flow (TTM)

172.20M

Free Cash Flow (TTM)

-44.03M

Capital Expenditure (TTM)

-19.00K

Net Change in Cash (TTM)

40.82M

Analyst Trends and Forecast

1

Aug 25

5

Nov 25

1

Dec 25

2

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.28B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

7.50

Earnings Yield % (TTM)

-3.33%

Earnings Yield % (FWD)

-4.50%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.48

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$42.00K

Total Cash

$56.87M

Debt to Equity

0.00

Issuance of Debt (TTM)

-$42.00K

Repayment of Debt (TTM)

-$42.00K

Key Statistics

Open

$11.41

Close

$11.10

Volume / Avg.

1.01M / 1.80M

Day Range

$10.93 - $11.46

52 Wk Range

3.77 - 14.39

Market Cap

$1.42B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

46

Short Interest

13.95%

Days to Cover

11.06

About

Sector

Health Care

Industry

Pharmaceuticals

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary f...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Trevi Therapeutics (TRVI) stock?

A

You can purchase shares of Trevi Therapeutics (NASDAQ:TRVI) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Trevi Therapeutics (TRVI) competitors?

A

Other companies in Trevi Therapeutics’s space includes: Theravance Biopharma Inc (NASDAQ:TBPH), GH Research PLC (NASDAQ:GHRS), AtaiBeckley Inc (NASDAQ:ATAI), Xeris Biopharma Holdings Inc (NASDAQ:XERS) and Rapport Therapeutics Inc (NASDAQ:RAPP).

Q

What is the forecast, or price target, for Trevi Therapeutics (TRVI) stock?

A

Trevi Therapeutics has a consensus price target of $18.63.

Q

What is the current price for Trevi Therapeutics (TRVI)?

A

The stock price for Trevi Therapeutics (NASDAQ: TRVI) is $11.1 last updated February 9, 2026 at 4:00 PM EST.

Q

Does Trevi Therapeutics (TRVI) pay a dividend?

A

There are no upcoming dividends for Trevi Therapeutics.

Q

When is Trevi Therapeutics (NASDAQ:TRVI) reporting earnings?

A

Trevi Therapeutics does not have any upcoming earnings scheduled.

Q

Is Trevi Therapeutics (TRVI) going to split?

A

There is no upcoming split for Trevi Therapeutics.

Q

What sector and industry does Trevi Therapeutics (TRVI) operate in?

A

Trevi Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

People Also Watch

Theravance Biopharma Inc

Xeris Biopharma Holdings Inc

NASDAQ:XERS

$6.88

-1.15%

Rapport Therapeutics Inc

NASDAQ:RAPP

$27.28

%

ANI Pharmaceuticals Inc

NASDAQ:ANIP

$80.34

%

Phathom Pharmaceuticals Inc

NASDAQ:PHAT

$12.78

%

Ocular Therapeutix Inc

NASDAQ:OCUL

$9.67

2.50%

Key Statistics

Open

$11.41

Close

$11.10

Volume / Avg.

1.01M / 1.80M

Day Range

$10.93 - $11.46

52 Wk Range

3.77 - 14.39

Market Cap

$1.42B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

46

Short Interest

13.95%

Days to Cover

11.06

Recent Trevi Therapeutics Inc News

Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Avi Kapoor

This Adient Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Avi Kapoor

Dow Gains Over 100 Points; US Job Openings Increase In April

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-44.01M

Investing Cash Flow (TTM)

-87.37M

Financing Cash Flow (TTM)

172.20M

Free Cash Flow (TTM)

-44.03M

Capital Expenditure (TTM)

-19.00K

Net Change in Cash (TTM)

40.82M

Analyst Trends and Forecast

1

Aug 25

5

Nov 25

1

Dec 25

2

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.28B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

7.50

Earnings Yield % (TTM)

-3.33%

Earnings Yield % (FWD)

-4.50%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.48

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$42.00K

Total Cash

$56.87M

Debt to Equity

0.00

Issuance of Debt (TTM)

-$42.00K

Repayment of Debt (TTM)

-$42.00K

Key Statistics

Open

$11.41

Close

$11.10

Volume / Avg.

1.01M / 1.80M

Day Range

$10.93 - $11.46

52 Wk Range

3.77 - 14.39

Market Cap

$1.42B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

46

Short Interest

13.95%

Days to Cover

11.06

About

Sector

Health Care

Industry

Pharmaceuticals

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary f...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry